Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prospective trial of the Oncobox platform RNA sequencing bioinformatic analysis for personalized prescription of targeted drugs.
Comput Biol Med
January 2025
Oncobox Ltd., Moscow, Russia; World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia; PathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Electronic address:
Interrogating gene expression in tumor can identify up- and downregulated molecular targets of cancer drugs. Here we report the results of prospective clinical investigation of using RNA sequencing analysis for personalized cancer therapy. Transcriptomic profiles were analyzed using Oncobox platform that identifies altered expression of drug target genes and molecular pathways and builds a personalized rating of targeted therapeutics.
View Article and Find Full Text PDFRecreational marijuana legalization's impact and opioid death rates: A synthetic control approach.
Public Health
January 2025
American Institute for Economic Research, United States. Electronic address:
Objectives: To develop a more robust understanding of the relationship between increased recreational marijuana access and opioid overdose deaths. Increasing opioid-related deaths in conjunction with the rising popularity of liberalized marijuana laws make additional research examining the interrelation of both a timely and insightful question.
Study Design: We use synthetic control method to assess the impact of opening recreational marijuana dispensaries via recreational marijuana legalization (RML) on opioid death rates in Colorado, Washington, and Oregon.
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
JAMA
January 2025
Institut Jules Bordet, l'Université Libre de Bruxelles and Hôpital Universitaire de Bruxelles, Brussels, Belgium.
Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic cancer, a devastating sequela with a 12- to 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative breast cancer was chemotherapy after surgery. However, it was not known whether the addition of immune therapy to postsurgery chemotherapy would be beneficial.
View Article and Find Full Text PDFProlgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
Eur J Cancer
January 2025
JSC Biocad, St. Petersburg, Russia.
Background: Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing 'LALA' mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Methods: 292 patients with advanced non-squamous NSCLC were randomized 1:1 to receive 4 cycles of pemetrexed, platinum-based drug and either prolgolimab (3 mg/kg Q3W) or placebo followed by prolgolimab/placebo with pemetrexed until disease progression or toxicity (≤36 months).
A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022) Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.
Infect Disord Drug Targets
January 2025
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health, 4 Dostoyevskogo St., bldg 2, Moscow, 127473, Russia.
Background: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice.
Objective: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB.
Methods: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!